Welcome to the Lilly Sponsored Breakfast Symposium
Optimising Outcomes for HR+ HER2- EBC Patients Through Risk-Based Decision Making.
You’re invited to an engaging and practical symposium exploring how risk-based decision-making is shaping the management of hormone receptor-positive, HER2-negative early breast cancer (HR+/HER2- eBC). As treatment options continue to evolve, accurately assessing risk has become increasingly important to help personalise therapy, optimise outcomes, and balance treatment benefit with potential toxicity.
Join internationally recognised expert Professor Giuseppe Curigliano, alongside Dr Belinda Kiely and Dr Nick Zdenkowski, as they explore:
- The latest evidence supporting risk-based treatment decisions in HR+/HER2- early breast cancer.
- Practical approaches to identifying patients who may benefit from treatment escalation or de-escalation.
- Interactive case studies demonstrating how risk assessment can guide management in real-world clinical practice.
- An expert panel discussion providing diverse clinical perspectives and the opportunity to ask questions of the faculty.
Don’t miss this opportunity to gain valuable insights from leading specialists, explore practical strategies for optimising outcomes in HR+/HER2- early breast cancer, and connect with colleagues from across the oncology community. We look forward to seeing you there!
Meet our Guest Speakers
We are pleased to introduce the following speakers at the Lilly sponsored Breakfast Symposium.
Giuseppe Curigliano
International Guest Speaker
Giuseppe Curigliano
International Guest Speaker
Giuseppe Curigliano, MD, PhD, is the director of the Early Drug Development Division and holds the co-chair for Experimental Therapeutics Program at the European Institute of Oncology, a comprehensive cancer center in Milano, Italy. He is a steering committee member of the Department of Oncology and Hemato-Oncology at the University of Milano. Moreover, he is a member of the Italian National Health Council, serving as advisor of the Ministry of Health for cancer policy issues.
He worked at the Columbia University Comprehensive Cancer Center in New York, USA, developing experience in preclinical and translational research. He was also a visiting scholar at the Dana Farber Cancer Institute, Harvard Medical School in Boston, USA. At the European Institute of Oncology, he served as Co-Director of the Division of Medical Oncology until 2014.
Professor Curigliano obtained his medical and specialist degree from the Catholic University in Rome, Italy. He is a specialist in Medical Oncology. He obtained a PhD in Clinical Pharmacology at the University of Pisa, Italy.
Professor Curigliano served as an expert panel member issuing the AIOM, ESMO, and ASCO guidelines in breast cancer and germline gene testing recommendations. He co-chaired for several years the scientific committee of the St Gallen Early Breast Cancer Conference. He is also a scientific board member of EUSOMA (European Society of Breast Cancer Specialists). He is serving as a member of the Scientific Board of the International Breast Cancer Study Group (IBCSG). He is serving on the executive board of the Breast International Group (BIG).
Professor Curigliano is the principal investigator and steering committee member of numerous breast and early development clinical trials, particularly with innovative targeted compounds and individualized treatment strategies. His translational research focusses on the field of biomarkers and personalised therapies, biomarker discovery, development of targeted agents, and implementation of personalised medicine. His team includes 40 people (including medical staff, research nurse, oncology nurse, and medical oncology residents) working on basic sciences, bioinformatics, biotechnologies, and clinical research. He is also leading phase I-III trials testing targeted agents in the field of breast cancer, agnostic and large national trials testing the implementation of high-throughput technologies in the health care system.
He has a strong interest in artificial intelligence and established in the University of Milano the first Master's in Artificial Intelligence in Cancer Medicine.
Belinda Kiely
Medical Oncologist
Belinda Kiely
Medical Oncologist
Associate Professor Belinda Kiely is a medical oncologist who specialises in breast cancer. She works at Campbelltown and Concord hospitals in Sydney, Australia.
She is an honorary clinical research fellow at the University of Sydney and enjoys supervising PhD students.
Her research interests include breast cancer treatment, survivorship, and prognostication in advanced cancer. A/Prof Kiely is an active member of Breast Cancer Trials.
She is the Australian study chair of the OPTIMA clinical trial and is the chair of the BCT Supportive Care Subgroup.
A/Prof Kiely is co-chair of the Medical Oncology Group of Australia Breast Cancer Group and a member of the Breast Cancer Network Australia Strategic Advisory Group.
Nick Zdenkowski
Conference Guest Speaker
Nick Zdenkowski
Conference Guest Speaker
Dr Zdenkowski is a Medical Oncologist and Medical Advisor with Breast Cancer Trials.
He is the Chair of the BCT Scientific Advisory Committee and sits on the international PALLAS trial Steering Committee. He works on a broad range of breast cancer research, including shared decision-making, clinical trials, and patient-reported outcomes, particularly around neoadjuvant systemic therapy.
His PhD project resulted in the development of a decision aid for patients considering neoadjuvant systemic therapy for breast cancer. He has published widely, from patient-reported outcomes, and systematic reviews through to clinical trial outcomes. His clinical practice is at Lake Macquarie Private Hospital and Maitland Private Hospital in the Hunter Region in NSW Australia.